Inhibikase Therapeutics shares owned by UBS Group
Quarter-by-quarter ownership of Inhibikase Therapeutics (IKT) shares owned by UBS Group
from 13F filings
Historical chart of UBS Group investment in Inhibikase Therapeutics
Tip: Access up to 7 years of quarterly data
All positions including Inhibikase Therapeutics held by UBS Group consolidated in one spreadsheet with up to 7 years of data
Download as csv

Quarterly reported holdings in Inhibikase Therapeutics by UBS Group
Quarter filed | Position value | Share count | Share price at filing |
---|---|---|---|
2024-12-31 | $90k | 28k | 3.25 |
2024-09-30 | $6.3k | 4.9k | 1.30 |
2024-03-31 | $6.9k | 3.2k | 2.16 |
2023-09-30 | $207 | 149 | 1.39 |